Orthogon Therapeutics raised $5.2M in a funding round to advance its first oral therapy for BK Polyomavirus.
Orthogon Therapeutics raised $5.2M in a funding round to advance its first oral therapy for BK Polyomavirus.
12/10/24, 1:33 PM
Location
cantonMoney raised
$5.2 million
Industry
biotechnology
science and engineering
health care
information technology
Orthogon Therapeutics announced the closing of an oversubscribed financing round, exceeding its $5M target. The funding will accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients.
Company Info
Location
canton, massachusetts, united states
Additional Info
Orthogon Therapeutics is a privately held R&D company. Orthogon uses structure-based drug design and biophysics to successfully optimize drugs that bind selectively and safely neutralize target proteins that have been considered difficult to “drug”. The Company was founded by a veteran biotech entrepreneur and experienced drug discovery scientists with a mission to prolong and improve patient quality of life.